Compare Boston Scientific Corporation (BSX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Wheaton Precious Metals Corp — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Wheaton Precious Metals Corp trades at $108.48 (market cap $48.84B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Wheaton Precious Metals Corp pays a 0.72% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | WPM | |
|---|---|---|
Market Cap | $66.37B | $48.84B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $165.72 |
52-Week Low | $42.63 | $88.32 |
Enterprise Value | $75.94B | $46.68B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Wheaton Precious Metals (WPM) trades at $107.83, down 2.02% today, showing bearish technical signals with strong resistance at $108-$110. Fundamentally, the company demonstrates robust performance with Q1 2026 EPS beating expectations at $1.28 versus $1.24, continuing a trend of earnings surprises. Revenue grew to $2.31 billion in 2025 with impressive 65.55% net income margin, though valuation ratios remain elevated with P/E at 27.25.
The stock presents a compelling opportunity with 80% analyst buy ratings and $161.75 consensus price target, representing 50% upside potential. Key risks include precious metal price volatility and the bearish technical outlook. Record cash flow generation and strong production growth support the positive fundamental story despite near-term price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
